Cognition Therapeutics, Inc.

Contributing Author

Recent Articles by Cognition Therapeutics, Inc.

Apr-07	Cognition Therapeutics to Present at Needham Virtual Healthcare Conference CGTX GlobeNewswire
Mar-31	Cognition Therapeutics CEO Issues Letter to Shareholders CGTX +27.73% CGTX +17.37% GlobeNewswire
Mar-26	Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update CGTX GlobeNewswire
Mar-23	Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results CGTX +5.61% GlobeNewswire
Mar-17	Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 CGTX +6.48% GlobeNewswire
Mar-02	Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis CGTX GlobeNewswire
Feb-05	Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies CGTX GlobeNewswire
Jan-27	Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies CGTX GlobeNewswire
Jan-06	Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies CGTX GlobeNewswire
Dec-03	Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies CGTX +11.80% GlobeNewswire
Dec-01	Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference CGTX -7.47% GlobeNewswire
Nov-20	Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference CGTX GlobeNewswire
Nov-13	Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease CGTX -10.47% GlobeNewswire
Nov-06	Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs CGTX GlobeNewswire
Sep-03	Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target CGTX GlobeNewswire
Sep-02	Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) CGTX GlobeNewswire
Aug-27	Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock CGTX -18.95% GlobeNewswire
Aug-26	Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement CGTX -10.22% GlobeNewswire
Aug-12	Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease CGTX +28.10% CGTX +10.91% GlobeNewswire
Aug-07	Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs CGTX +11.45% CGTX GlobeNewswire
Jul-29	Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease CGTX -6.28% GlobeNewswire
Jul-21	Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease CGTX +7.03% GlobeNewswire
Jul-16	Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC CGTX +8.56% GlobeNewswire
Jul-10	Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease CGTX +31.45% GlobeNewswire
Jul-01	Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target CGTX GlobeNewswire
Jun-25	Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB) CGTX GlobeNewswire
Jun-03	Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies CGTX GlobeNewswire
May-28	Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies CGTX -5.76% GlobeNewswire
May-09	Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health CGTX -8.76% GlobeNewswire
May-08	Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy CGTX -6.96% GlobeNewswire
May-07	Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update CGTX -15.04% GlobeNewswire

Cognition Therapeutics, Inc.

Recent Articles by Cognition Therapeutics, Inc.

Upgrade your Finviz experience